Гидроксифенилпропамидобензойная кислота is a skin-conditioning active used in formulations designed for sensitive or reactive-feeling skin. For a cosmetic buyer, however, the commercial name is only the start. A defensible purchase decision must connect identity, assay, impurity control, manufacturing origin, solubility, finished-product stability, safety substantiation, and claim language.
This guide explains how procurement and formulation teams can qualify ZLEY Hydroxyphenyl Propamidobenzoic Acid, design a practical bench program, interpret the published evidence without overstating it, and prepare a useful supplier RFQ.
Краткий ответ: Hydroxyphenyl Propamidobenzoic Acid, also called dihydroavenanthramide D, is a synthetic analogue of naturally occurring oat avenanthramides. ZLEY supplies it as a white to off-white powder that is slightly soluble in water and soluble in alcohols. ZLEY’s published recommendation is up to 2% in leave-on body and eye-area products, but that is a supplier recommendation, not a universal legal limit or an automatic finished-product use level.
What Is Hydroxyphenyl Propamidobenzoic Acid?
Hydroxyphenyl Propamidobenzoic Acid is the INCI name for the substance also known as dihydroavenanthramide D. It is an oat-inspired molecule, but published research describes it as a synthetic avenanthramide analogue. That distinction matters for natural-origin, vegan, allergen, and marketing statements.
| Поле «Идентификатор» | Сведения о покупателе | Последствия для закупок |
|---|---|---|
| ИНКИ | Гидроксифенилпропамидобензойная кислота | Use the exact INCI on specifications, safety assessments, and ingredient lists. |
| CAS | 697235-49-7 | Match the CAS across the COA, SDS, TDS, regulatory statement, and supplier questionnaire. |
| Formula | C16H15NO4 | Подтверждено в Запись идентификационных данных в системе GSRS Управления по контролю за продуктами и лекарствами (FDA). |
| UNII | 25KRT26H77 | An identity code, not evidence of FDA approval. |
| Номер списка ЕС | 690-968-6 | Показано в Запись о веществе в базе данных ECHA; confirm the current regulatory context for each market. |
| Common research name | Dihydroavenanthramide D, often abbreviated DHAvD | Use this name when searching scientific literature, but keep the INCI on commercial documentation. |
| Trade-name references | Some public records include third-party trade names | Do not transfer another supplier’s dossier, concentration, or claim support to a different grade without equivalence data. |
What the Published Evidence Shows
The evidence supports further formulation work, but it does not justify treating every product containing the ingredient as clinically proven. The study model, concentration, vehicle, endpoint, and sample size must travel with every claim.
| Доказательства | Useful finding | Important limitation |
|---|---|---|
| 2017 mechanistic study | Dihydroavenanthramide D interacted with the neurokinin-1 receptor and inhibited mast-cell degranulation in the reported models. | Mechanistic evidence is not a finished-product consumer claim. Vehicle, exposure, and endpoint validation still matter. |
| 2013 human fibroblast study | The ingredient reduced UVB-associated ROS generation and MMP-1/MMP-3 expression in cultured human dermal fibroblasts. | This was an in-vitro photoaging model, not proof that a market formula prevents or reverses photoaging in people. |
| 2024 barrier study | Cell and reconstructed-skin work reported restoration of tight-junction and differentiation markers. In a two-week formula test on six sensitive-skin subjects, reported TEWL fell from 24.3 to 17 and the glycolic-acid sting score fell from 2.33 to 0.67. | The in-vivo subgroup was very small, used a specific formula at 24.5 micrograms/mL, and was not a broad population efficacy trial. Treat the numbers as hypothesis-supporting, not universal benchmarks. |
| 2009 human-skin diffusion study | Microemulsion composition and 1,2-alkanediols influenced dermal and transdermal delivery of dihydroavenanthramide D. | This was a delivery study. It shows that the vehicle matters; it does not establish the best commercial formula or claim level. |
| Published contact-allergy case report | Allergic contact dermatitis was attributed to Hydroxyphenyl Propamidobenzoic Acid in a skin-calming cream after patch testing. | A single case does not establish population incidence, but it disproves any assumption that a soothing active is incapable of sensitization. |
How Buyers Should Interpret the Evidence
- Use mechanism data to design tests, not to skip them. Cell, mast-cell, and reconstructed-skin results can support a development hypothesis. Consumer-facing wording requires evidence from the finished formula and intended use conditions.
- Keep concentration and vehicle attached to the result. A neat raw material, a glycol solution, an emulsion, and a surfactant cleanser can produce different delivery and tolerance profiles.
- Separate cosmetic comfort claims from disease claims. Language about treating eczema, dermatitis, allergy, or inflammation may change product classification in some markets.
- Do not equate a low search-result hazard score with a safety assessment. The toxicological profile, impurities, exposure, target population, application area, and finished formula all belong in the assessment.
- Record negative evidence. The contact-allergy case should be part of the safety review even though the ingredient is commercially positioned for sensitive-skin products.
Hydroxyphenyl Propamidobenzoic Acid Supplier Specifications
A quotation without a controlled specification is not enough. Ask potential suppliers to identify the analytical method, acceptance criteria, and change-control process for every material attribute that can affect the formula.
| Область спецификации | Что заказать | Почему это важно |
|---|---|---|
| Идентичность | INCI, CAS, chromatographic or spectroscopic identity method, and reference-standard traceability | Prevents confusion with solutions, blends, salts, or differently concentrated commercial grades. |
| Анализ | Active-content range, test method, system suitability, and reporting basis | Allows accurate dosing and meaningful stability trending. |
| Связанные вещества | Named and total impurity limits plus an analytical chromatogram where available | Impurities can influence color, odor, sensitization risk, and long-term stability. |
| Остаточные растворители | Solvent list, limits, and method aligned with the manufacturing route | Supports toxicological review and customer-restricted-substance requirements. |
| Moisture or loss on drying | Method and acceptance range | High or variable moisture can change assay-by-weight and powder handling. |
| Appearance and color | Controlled visual or instrumental criteria | Yellowing or darkening can signal lot variation, oxidation, or storage exposure. |
| Particle behavior | Particle-size information where relevant, bulk density, and dispersion notes | Affects wetting, dust control, dissolution time, sampling, and scale-up. |
| Solution behavior | Solubility data in water, ethanol, selected glycols, and the intended preblend | Prevents clear-at-make batches from crystallizing during storage. |
| Загрязняющие вещества | Heavy metals, microbiological quality where relevant, and restricted-substance declarations | Необходимо для обеспечения соответствия требованиям рынка и клиентов; лимиты должны устанавливаться с учетом рисков. |
| Стабильность | Retest period, storage conditions, packaging, and available stability basis | Supports warehouse controls and shelf-life decisions. |
Clarify Oat Association and Manufacturing Origin
Hydroxyphenyl Propamidobenzoic Acid is structurally inspired by avenanthramides found in oats. That does not, by itself, prove that a commercial lot is extracted from oats or manufactured from oat-derived feedstocks. Published studies commonly describe dihydroavenanthramide D as synthetic.
When natural-origin, oat-free, gluten-free, vegan, non-GMO, or allergen statements are commercially important, ask for a signed origin statement covering feedstocks, processing aids, cross-contact controls, and the exact grade. Do not infer those claims from the INCI name or from a marketing description. The same rule applies when transferring data from a third-party trade ingredient: confirm composition, active content, solvents, impurities, and analytical equivalence first.
Formulation Workflow for a Stable Finished Product
ZLEY describes the material as slightly soluble in water and soluble in alcohols. The practical formulation risk is not only whether the powder disappears during manufacturing, but whether the active remains dissolved, recoverable, and evenly distributed after cooling, pH adjustment, fragrance addition, packaging, and storage.
- Define the dosage basis. Confirm whether the supplier percentage refers to neat active or a diluted commercial solution. ZLEY’s product page lists up to 2% for leave-on body and eye-area products; treat this as a supplier recommendation that still requires a market-specific safety assessment.
- Составьте карту растворителей. Measure clarity and active recovery in candidate alcohols and glycols at room temperature and at the proposed processing temperature. Include the complete solvent blend, not only each solvent in isolation.
- Prepare a controlled preblend. Add the active gradually under sufficient mixing and record time, temperature, order of addition, and solution appearance. A transparent preblend is not automatically stable after dilution into the main batch.
- Choose the addition point from data. If robust thermal-degradation data are unavailable, introduce the preblend during cool-down at the lowest temperature that still gives complete incorporation. Do not assume heat stability from short-term visual clarity.
- Map pH and electrolyte effects. Evaluate the full pH specification and realistic manufacturing drift. Check whether neutralization, salts, polymers, or surfactants cause haze, crystals, viscosity loss, or assay variation.
- Add fragrance and preservation before final judgment. Fragrance oils and solubilizers can compete for solvent capacity. The active is not a substitute for a validated broad-spectrum preservation system.
- Проверьте, работает ли функция восстановления. Use a validated extraction and assay method at time zero and during stability. Visual inspection alone cannot distinguish dissolution, adsorption, degradation, or sampling error.
A Practical Pilot Matrix
For early screening, a procurement team can request enough sample for a solvent control plus 0.1%, 0.5%, and 1.0% active prototypes. A 2.0% prototype should be added only when the target market, safety assessment, claim plan, and supplier documentation support testing near the supplier’s published ceiling. These are development brackets, not recommended final levels.
| Pilot | Цель | Decision gate |
|---|---|---|
| Vehicle control | Separates solvent and base-formula effects from active effects | Baseline appearance, viscosity, tolerance, and claim endpoint |
| Low active level | Tests minimum practical incorporation and early benefit signal | Assay recovery, clarity, and formula-specific performance |
| Mid active level | Explores dose response without approaching the ceiling | Incremental benefit relative to cost and tolerance |
| High active level | Challenges solvent capacity, stability, and safety margin | No crystallization, acceptable exposure assessment, and justified claim value |
| Fragrance or package variants | Tests realistic commercial changes | No loss of clarity, assay, viscosity, compatibility, or user tolerance |
Распространенные ошибки при составлении рецептур и меры по их устранению
| Констатированный сбой | Вероятная причина | Корректирующие меры |
|---|---|---|
| Кристаллы после охлаждения | Supersaturated preblend or insufficient solvent capacity in the finished formula | Reduce the active or preblend concentration, screen another approved solvent system, and repeat low-temperature storage. |
| Haze after pH adjustment | Ionization or solubility changed across the pH range | Map the entire pH specification with the complete formula and confirm assay recovery. |
| Спад вязкости | Alcohol, glycol, electrolyte, or active preblend shifted polymer hydration or the surfactant salt curve | Rebuild rheology with the active present and make final viscosity adjustment after all functional materials are added. |
| Цветовой дрейф | Impurity variation, oxidation, light exposure, packaging interaction, or fragrance reaction | Compare lots, monitor degradants, use controlled light exposure, and evaluate antioxidant or packaging changes only after root-cause work. |
| Variable assay | Incomplete extraction, adsorption, crystals, non-representative sampling, or degradation | Validate sample preparation and analytical recovery before changing the formula. |
| Good assay but weak consumer result | The endpoint, vehicle, dose, duration, or population does not match the intended claim | Redesign the finished-product study instead of relying on raw-material literature alone. |
Stability, Safety, and Claim Substantiation
A high-quality development program connects each test to a launch decision:
- Физическая устойчивость: appearance, color, odor, crystal inspection, pH, viscosity, centrifuge screening, temperature cycling, freeze-thaw where relevant, and long-term storage.
- Химическая стойкость: active assay, related substances, and validated sample recovery at defined intervals.
- Совместимость упаковки: active recovery, discoloration, paneling, leakage, closure function, and adsorption in the final pack.
- Микробиологическое качество: routine limits and a finished-product preservative efficacy or challenge test.
- Safety: exposure-based toxicological assessment, target-population review, market-appropriate compatibility testing, and an eye-area assessment when applicable.
- Sensitization risk: review the published contact-allergy case, supplier sensitization data, impurities, and finished-product patch-test strategy. Avoid absolute terms such as “non-allergenic” or “zero irritation.”
- Claims: predefine the endpoint, comparator, population, use frequency, duration, statistics, and acceptance criteria for the finished formula.
For sensitive-skin positioning, a useful claim package may combine instrumental barrier measures such as TEWL with a controlled discomfort or stinging assessment and investigator grading. The protocol must fit the intended wording. A raw-material study cannot automatically substantiate the same claim for a new finished product.
EU and U.S. Regulatory Screening
| Market | Screening point | Действия покупателя |
|---|---|---|
| Евросоюз | The 2025 common-ingredient-name glossary decision may be used during the transition through 29 July 2026 and applies from 30 July 2026. A glossary name supports labeling; it is not, by itself, a safety approval or a concentration authorization. | Check the current Cosmetics Regulation, Annexes, CPSR, PIF, claims file, exposure, impurities, and target population at launch. |
| Соединенные Штаты | The FDA GSRS page confirms substance identity, but the page itself states that a UNII does not imply regulatory review or approval. | Do not describe the ingredient or formula as “FDA approved.” FDA explains that cosmetics and most cosmetic ingredients do not receive premarket approval, while marketers remain responsible for safety and labeling. Review the Руководство FDA по косметическим ингредиентам. |
| Claims in any market | Statements about treating eczema, dermatitis, allergy, inflammation, or other disease can move beyond cosmetic positioning. | Review labels, websites, sales decks, distributor copy, and social content together. In the U.S., use the Концепция FDA в отношении предполагаемого назначения. |
Важно: a supplier recommendation is not a legal maximum, an INCI listing is not an approval, and a legal maximum is not a formula recommendation. Confirm all three questions separately.
Контрольный список по запросам предложений для отделов закупок
Send enough context for the supplier to identify technical and regulatory risk before quoting:
- Target countries, launch date, product type, application area, and intended claims.
- Whether the formula is leave-on, rinse-off, facial, body, eye-area, scalp, or another exposure scenario.
- Target active level and whether the percentage is based on neat active or a commercial solution.
- Base formula, pH specification, processing temperature, solvent restrictions, fragrance status, and packaging.
- Required specification, COA, TDS, SDS, analytical method, impurity profile, residual-solvent statement, and stability data.
- Origin, allergen, oat-contact, vegan, GMO, and restricted-substance declarations where commercially relevant.
- Sample quantity, pilot size, annual forecast, packaging size, Incoterm, destination, and required lead time.
- Change-control notice period, retest period, minimum shelf life at receipt, and audit requirements.
- Need for formulation troubleshooting, active-assay support, or a market-specific regulatory package.
For broader sensitive-skin concept development, review ZLEY’s Ectoin formulation and sourcing guide, который ZLEY Ectoin product page, and our поддержка в разработке рецептур.
Часто задаваемые вопросы
Is Hydroxyphenyl Propamidobenzoic Acid the same as oat extract?
No. It is a defined synthetic analogue of avenanthramides associated with oats, not a generic Avena sativa extract. Verify manufacturing origin and cross-contact documentation before making natural-origin or oat-free statements.
Is Hydroxyphenyl Propamidobenzoic Acid water soluble?
ZLEY describes it as slightly soluble in water and soluble in alcohols. Screen the complete solvent and formula system because clarity in a concentrated preblend does not guarantee stability after dilution, cooling, pH adjustment, or fragrance addition.
What use level should a formulator start with?
ZLEY publishes a ceiling of up to 2% for leave-on body and eye-area applications. For early formulation work, a vehicle control plus 0.1%, 0.5%, and 1.0% prototypes can reveal solubility, stability, tolerance, and dose-response behavior. Select the final level from market regulation, safety, formula performance, claim evidence, and cost.
Can the ingredient support sensitive-skin positioning?
Published mechanistic, reconstructed-skin, and limited human data support further development. The finished product still needs formula-specific tolerance and claim substantiation. A published allergic-contact-dermatitis case means absolute non-allergenic language is not defensible.
Can it be called oat-derived?
Not from the INCI name alone. Scientific papers commonly describe dihydroavenanthramide D as synthetic. Use a supplier origin statement and traceable feedstock documentation for any natural-origin or oat-derived claim.
Does a UNII mean FDA approved?
No. FDA states on its substance record that UNII availability does not imply regulatory review or approval. U.S. cosmetic marketers remain responsible for ingredient and finished-product safety, labeling, and intended-use compliance.
Regulatory and scientific information in this article is a formulation-screening reference. Recheck current official requirements, supplier documentation, and finished-product evidence for every target market and claim.